Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785919 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 | |
| SCHEMBL785447 | 0.83 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL785699 | 0.83 | ALDH1A1 (0.45) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 | |
| SCHEMBL785014 | 0.82 | ALDH1A1 (0.49) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 | |
| SCHEMBL785015 | 0.82 | ALDH1A1 (0.49) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 | |
| SCHEMBL785364 | 0.82 | TAS1R3 (0.44) | KMT2AALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL785762 | 0.82 | ALDH1A1 (0.44) | KMT2AALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL784081 | 0.82 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL784261 | 0.82 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL784823 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | USP30 4164/4885MEN1 2563/4885KMT2A 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.